Fabry Disease Treatment Market (By Treatment: Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 160

Introduction

The global fabry disease treatment market size is anticipated to around USD 3.9 billion by 2026, this market is anticipated to grow with 10.1% CAGR during the forecast time period.

Market Dynamics

Increasing cohort of Fabry infection, expanding adoption of novel treatments, for example, chaperone treatment, and potential endorsement of pipeline drugs including substrate decrease treatments and compound substitution treatments are giving a fillip to the market.

Fabry ailment is an uncommon acquired lysosomal stockpiling issue caused by hereditary transformation that meddles with capacity of alpha galactosidase protein. Fabry illness for the most part has a late beginning with mellow manifestations, because of which a few patients are frequently undiscovered. Standard of consideration for the board of the sickness is catalyst substitution treatment (ERT). Sanofi's Fabrazyme and Shire's Replagal are the main endorsed ERTs in the EU; anyway in the U.S., just Fabrazyme has been affirmed.

Market Insights

Growing base of patients suffering with Fabry illness combined with expanded appropriation of novel treatments, for example, chaperone treatment has helped the market gain energy. Other than this, broad R&D exercises and potential endorsement of promising pipeline products including substrate decrease treatments and compound substitution treatments are anticipated to raise the development of the over the forecast period.

Fabry sickness is an uncommon X-connected lysosomal storage issue with an insufficiency of alpha galactosidase chemical bringing about dynamic organ brokenness. This illness is caused by unusual development of a particular greasy issue called globotriaosylceramide in different tissues of the body including eyes, skin, kidney, gastrointestinal system, central nervous system and heart, brain.

Patients suffering Fabry disease regularly advancement to a phase of serious torment of furthest points, compromised kidney work frequently advancing to full kidney disappointment, early heart issue, stroke, and incapacitating gastrointestinal side effects. In view of the absence of a therapeudic answer for Fabry disease, treatment alternatives for the most part go for the board of inconveniences related with infection movement and giving symptomatic alleviation.

Market Segmentation

Market By Treatment

  • Enzyme Replacement Therapy (ERT)
  • Chaperone Treatment
  • Substrate Reduction Therapy (SRT)
  • Others

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Regional Insights

Asia Pacific presents massive development open doors for pharmaceutical organizations because of expanding human services consumption and improving infrastructure. The locale is probably going to encounter the quickest development during the coming years, trailed by Latin America, essentially because of substantial populaces in rising nations.North America was the most prominent regional market in 2018, trailed by Europe. Higher selection of novel treatments, better social insurance offices, and great repayment arrangements are assuming a crucial job in the development of the market in the region. Inclusion of costly prescriptions, for example, Fabrazyme by health insurance programs and good legislative medicinal services arrangements are likewise inciting medication organizations to build R&D demand in the field of rare diseases.

Market Participants

Few of the main businesses present in the global Fabry Disease Treatment market are Green Cross Pharma Pte Ltd.; Sanofi S.A.; Moderna Therapeutics Inc.; Shire Plc.; Greenovation Biotech Avrobio Inc.; GmbH; Amicus Therapeutics Inc.; Idorsia Pharmaceuticals Ltd.; ISU Abxis Co Ltd.; JCR Pharmaceuticals Co Ltd. and ProtalixBiotherapeutics Inc.Significanttactical initiatives undertaken by global industries include partnerships, acquisitionsand new product launch.


Related Reports

Meningococcal Vaccines Market (By Type: Combination Vaccines [MenHibrix, Menitorix], Conjugate Vaccines [Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT], Polysaccharide [Mencevax, Menomune, NmVac4, Others], Men B Vaccines [Bexsero, Trumenba], Others; By End User: Retail Pharmacies, Hospital Pharmacies, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Introduction: Meningococcal vaccines are utilized to treat meningitis brought about by bacterium N. meningitidis. Beforehand there were no careful steps accessible to maintain a strategic distance from meningitis. Anti-infection agents alongside supplement supplements were utilized to treat this ailment after the disease was affirmed. In any case, with the approach of the meningoco

Real-time PCR (qPCR) and Digital PCR (dPCR) Market (By Technology: Digital, Quantitative; By Product: Instruments, Reagents and Consumables, Software & Services; By Application: Research [Forensic and Others], Clinical [Pathogen Testing, Oncology Testing, Blood Screening, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Introduction According to Acumen Research and Consulting, the global Real-time PCR (qPCR) & Digital PCR (dPCR) market is expected to grow at noteworthy CAGR around 8.1 % throughout the forecast period and reach around US$ 4.2 billion by 2026. In order to amplify or make more copies of the deoxyribonucleic acid (DNA) sequence

Nebulizer Market (By Type: Mesh, Pneumatic [Portable, Standalone], Ultrasonic [Portable, Standalone) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Introduction According to Acumen Research and Consulting, the global Nebulizer market is expected to grow at noteworthy CAGR around 6.2 % throughout the forecast period and reach around US$ 1.4 billion by 2026. Nebulizer is a medical device that converts the medicine into a nebula and directly into the pulmonary system. Nebuliza

Motion Preservation Devices Market (By Product: Total Disc Replacement Devices, Prosthetic Nucleus Replacement Devices, Posterior Dynamic Devices, Facet Replacement Devices; By Surgery: Open Spine Surgery, Minimally Invasive Spine Surgery; By End Use: Hospitals, Ambulatory Surgical Centers, Orthopedic Centers and Clinics) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Introduction According to Acumen Research and Consulting, the global Motion Preservation Devices market is expected to grow at noteworthy CAGR around 10.5 % throughout the forecast period and reach around US$ 1.5 billion by 2026. In spinal disorders, movement preservation devices are used. Motion conservation devices are used to

Hemoglobinopathy Market (By Type: Thalassemia [Beta Thalassemia, Alpha Thalassemia], Sickle Cell Disease, Other Hb Variants Diseases; By Therapy: Thalassemia [Beta Thalassemia, Alpha Thalassemia], Sickle Cell Disease, Other Hb Variants Diseases; By Diagnosis: Thalassemia [Beta Thalassemia, Alpha Thalassemia], Sickle Cell Disease, Other Hb variants diseases) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Introduction According to Acumen Research and Consulting, the global Hemoglobinopathy market is expected to grow at noteworthy CAGR around 10 % throughout the forecast period and reach around US$ 12 billion by 2026. Hemoglobinopathy is a genetic disorder that causes structural abnormalities in hemoglobin molecules. Hemoglobinopa

Cart Summary